drugset
drugset / Trial / NCT04908514

A Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of Subjects With Plaque Psoriasis

NCT04908514 ↗

Phase 2 Completed 10 enrolled Aldeyra Therapeutics, Inc.
NaSingle-groupOpen-labelTreatment

Summary

A Multi-Center, Open-Label, Phase 2 Clinical Trial to Evaluate the Safety, Tolerability, and Efficacy of ADX-629 Administered Orally to Subjects with Plaque Psoriasis

Timeline

Start
2021-05-07
Primary completion
2022-01-21
Completion
2022-01-21

Drugs

EvaluationDrugModalityDoseRoute
Subject ACLOPROXALAP Other / unclassified 250 mg Oral

Indications

psoriasis